Authors' reply to letter by Martinod et al. on rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.

Saved in:
Bibliographic Details
Title: Authors' reply to letter by Martinod et al. on rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
Authors: Katoh H, Okamoto R, Ozawa Y, Tokito T, Kikuchi M, Sangai T
Source: European thyroid journal [Eur Thyroid J] 2025 Dec 24; Vol. 14 (6). Date of Electronic Publication: 2025 Dec 24 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Bioscientifica Ltd Country of Publication: England NLM ID: 101604579 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 2235-0802 (Electronic) Linking ISSN: 22350640 NLM ISO Abbreviation: Eur Thyroid J Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2235-0802
DOI:10.1530/ETJ-25-0377